Study of RXDX-105, Potent RET Inhibitor in Patients With Advanced Lung Cancer and Other Solid Tumors
Status:
Completed
Trial end date:
2019-02-01
Target enrollment:
Participant gender:
Summary
This is a first-in-human, multicenter, open-label study consisting of 2 phases. Phase 1 is a
dose escalation study of RXDX-105 (formerly known as CEP-32496) in patients with advanced
solid tumors aimed at defining the recommended Phase 2 dose (RP2D) and schedule for
administration. Phase 1b is a dose expansion in approximately 90 patients with advanced solid
tumors with specific histologies and/or molecular alterations of interest. Patients in Phase
1b will be treated at the RP2D determined in Phase 1.